CST3 and cardiovascular disorder: These data support the use of eGFRcys for people of African and Caribbean ancestry where available, and, in particular, focused use of cystatin C to delineate individuals at higher risk of developing worsening renal function, cardiovascular disease, or mortality, or to exclude a CKD diagnosis in the absence of proteinuria.